

Press release
30 April, 2025

Curasight to present at HC Andersen Capital

Copenhagen, Denmark, 30 April 2025 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO professor Andreas Kjær will present the Right Issue of new shares and the company's latest progress at HC Andersen Capital

The presentations will include a presentation of the Right Issue of new shares and an update on the business progress made by the company during the first quarter of 2025. In addition, management will update investors on the latest developments in the first quarter and expected news flow about the pipeline.

The HC Andersen Capital presentation will be webcasted live 13:00 - 13:30 (CET), Friday 2 May 2024 focusing on the ongoing Right Issue.

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight's website, after the presentation is completed.

For more information – please [click here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.